Joseph Schwartz
Stock Analyst at Leerink Partners
(3.28)
# 1,050
Out of 5,042 analysts
149
Total ratings
34.09%
Success rate
21.35%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Joseph Schwartz
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RNA Avidity Biosciences | Downgrades: Market Perform | $65 → $72 | $69.85 | +3.08% | 4 | Oct 27, 2025 | |
| SPRB Spruce Biosciences | Maintains: Market Perform | $10 → $160 | $110.10 | +45.32% | 6 | Oct 21, 2025 | |
| CRNX Crinetics Pharmaceuticals | Maintains: Outperform | $80 → $88 | $43.50 | +102.30% | 2 | Sep 29, 2025 | |
| QURE uniQure | Maintains: Outperform | $48 → $68 | $67.69 | +0.46% | 2 | Sep 24, 2025 | |
| SRPT Sarepta Therapeutics | Maintains: Market Perform | $12 → $15 | $24.01 | -37.53% | 14 | Sep 9, 2025 | |
| KALV KalVista Pharmaceuticals | Maintains: Outperform | $18 → $20 | $10.91 | +83.32% | 6 | Jul 7, 2025 | |
| INSM Insmed | Maintains: Outperform | $100 → $115 | $189.60 | -39.35% | 4 | Jun 10, 2025 | |
| FULC Fulcrum Therapeutics | Upgrades: Outperform | $4 → $12 | $8.74 | +37.30% | 4 | May 23, 2025 | |
| MAZE Maze Therapeutics | Initiates: Outperform | $28 | $32.91 | -14.92% | 1 | Feb 25, 2025 | |
| TVTX Travere Therapeutics | Maintains: Outperform | $20 → $40 | $35.16 | +13.77% | 6 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $11 → $14 | $1.15 | +1,117.39% | 2 | Sep 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $1.23 | - | 3 | Jul 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $12 | $5.39 | +122.63% | 6 | Jun 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $6 → $8 | $1.90 | +321.05% | 2 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $1 | $1.69 | -40.83% | 4 | Feb 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $6 | $6.74 | -10.94% | 4 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $48 | $68.31 | -29.73% | 1 | Mar 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $18 | $22.14 | -18.70% | 5 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $33 → $34 | $74.30 | -54.24% | 1 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $122 → $130 | $53.57 | +142.67% | 10 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $148 → $163 | $201.60 | -19.15% | 15 | Jan 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $10 | $2.45 | +308.16% | 7 | Dec 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $33 | $4.66 | +608.15% | 2 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $17 → $12 | $13.17 | -8.88% | 6 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $115 → $108 | $34.60 | +212.14% | 6 | Nov 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $6 → $4 | $1.46 | +173.97% | 4 | May 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $34 → $30 | $18.28 | +64.11% | 2 | May 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $50 → $30 | $78.62 | -61.84% | 6 | May 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $14 | $9.03 | +55.04% | 12 | Feb 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $10 → $12 | $2.75 | +336.36% | 2 | Sep 26, 2017 |
Avidity Biosciences
Oct 27, 2025
Downgrades: Market Perform
Price Target: $65 → $72
Current: $69.85
Upside: +3.08%
Spruce Biosciences
Oct 21, 2025
Maintains: Market Perform
Price Target: $10 → $160
Current: $110.10
Upside: +45.32%
Crinetics Pharmaceuticals
Sep 29, 2025
Maintains: Outperform
Price Target: $80 → $88
Current: $43.50
Upside: +102.30%
uniQure
Sep 24, 2025
Maintains: Outperform
Price Target: $48 → $68
Current: $67.69
Upside: +0.46%
Sarepta Therapeutics
Sep 9, 2025
Maintains: Market Perform
Price Target: $12 → $15
Current: $24.01
Upside: -37.53%
KalVista Pharmaceuticals
Jul 7, 2025
Maintains: Outperform
Price Target: $18 → $20
Current: $10.91
Upside: +83.32%
Insmed
Jun 10, 2025
Maintains: Outperform
Price Target: $100 → $115
Current: $189.60
Upside: -39.35%
Fulcrum Therapeutics
May 23, 2025
Upgrades: Outperform
Price Target: $4 → $12
Current: $8.74
Upside: +37.30%
Maze Therapeutics
Feb 25, 2025
Initiates: Outperform
Price Target: $28
Current: $32.91
Upside: -14.92%
Travere Therapeutics
Oct 11, 2024
Maintains: Outperform
Price Target: $20 → $40
Current: $35.16
Upside: +13.77%
Sep 19, 2024
Maintains: Outperform
Price Target: $11 → $14
Current: $1.15
Upside: +1,117.39%
Jul 3, 2024
Upgrades: Outperform
Price Target: n/a
Current: $1.23
Upside: -
Jun 24, 2024
Upgrades: Outperform
Price Target: $12
Current: $5.39
Upside: +122.63%
Jun 20, 2024
Maintains: Outperform
Price Target: $6 → $8
Current: $1.90
Upside: +321.05%
Feb 9, 2024
Downgrades: Market Perform
Price Target: $1
Current: $1.69
Upside: -40.83%
Aug 15, 2023
Downgrades: Market Perform
Price Target: $6
Current: $6.74
Upside: -10.94%
Mar 17, 2023
Initiates: Market Perform
Price Target: $48
Current: $68.31
Upside: -29.73%
Feb 3, 2023
Maintains: Outperform
Price Target: $20 → $18
Current: $22.14
Upside: -18.70%
Feb 3, 2023
Maintains: Market Perform
Price Target: $33 → $34
Current: $74.30
Upside: -54.24%
Feb 3, 2023
Maintains: Outperform
Price Target: $122 → $130
Current: $53.57
Upside: +142.67%
Jan 17, 2023
Maintains: Outperform
Price Target: $148 → $163
Current: $201.60
Upside: -19.15%
Dec 7, 2022
Maintains: Outperform
Price Target: $15 → $10
Current: $2.45
Upside: +308.16%
Nov 10, 2022
Maintains: Outperform
Price Target: $40 → $33
Current: $4.66
Upside: +608.15%
Nov 4, 2022
Maintains: Outperform
Price Target: $17 → $12
Current: $13.17
Upside: -8.88%
Nov 3, 2022
Maintains: Outperform
Price Target: $115 → $108
Current: $34.60
Upside: +212.14%
May 12, 2022
Maintains: Outperform
Price Target: $6 → $4
Current: $1.46
Upside: +173.97%
May 12, 2022
Maintains: Outperform
Price Target: $34 → $30
Current: $18.28
Upside: +64.11%
May 5, 2022
Maintains: Outperform
Price Target: $50 → $30
Current: $78.62
Upside: -61.84%
Feb 24, 2022
Maintains: Outperform
Price Target: $16 → $14
Current: $9.03
Upside: +55.04%
Sep 26, 2017
Maintains: Outperform
Price Target: $10 → $12
Current: $2.75
Upside: +336.36%